• Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
    • Mergers & Acquisitions
  • Value-based Care

Syapse to Utilize NCCN Biomarkers Compendium for More Personalized Care

by Jasmine Pennic 11/01/2018 Leave a Comment

Share with your friends










Submit

Google Cancer Research

New partnership between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care.

The National Comprehensive Cancer Network(NCCN) announced a new agreement with Syapse, a precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. For Syapse, the data contained in theNCCN Biomarkers Compendium will strengthen Syapse’s decision support and workflow tools, increasing access to more personalized care.

NCCN Biomarkers Compendium

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.

The NCCN Biomarkers Compendium is part of NCCN’s Library of Compendia, which also includes databases for Drugs & Biologics (NCCN Compendium®), as well as the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™). The NCCN Compendium® is recognized by public and private insurers alike, including CMS and UnitedHealthcare, as an authoritative reference for oncology coverage policy. The recommendations contained in the Library of NCCN Compendia are extracted directly from the relevant NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and are updated on a continuous basis.

“Treatment recommendations for people with cancer are expanding and improving rapidly, and that is particularly the case with precision medicine,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “The experts who sit on the various NCCN Guidelines Panels are at the forefront of advances in using genes and gene products for diagnosis, screening, monitoring, surveillance, and other aspects of cancer care. The latest updates from our guidelines are included in the NCCN Biomarkers Compendium, which will now support the point-of-care decision-making tools from Syapse.”

“Harnessing technology to share the latest evidence- and expert consensus-based information on biomarkers allows clinicians to make well-informed decisions more efficiently,” said Dr. Carlson. “That means they’ll have more time for the patients who need them.”

Integration Roll-Out Plans

The NCCN-supported data will begin appearing on the Syapse platform in late 2018. Syapse is committed to updating that content weekly to keep pace with the NCCN Guidelines. Syapse clients include Aurora Health Care, Catholic Health Initiatives, Dignity Health, Henry Ford Health System, Intermountain Healthcare, Providence St. Joseph Health, and Seoul National University Hospital—manage one million active cancer cases at nearly 300 hospitals in 25 states and South Korea.

Tagged With: Cancer Diagnostics, precision medicine, Precision Medicine Oncology, Syapse

Share with your friends










Submit

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

« IntelyCare Nabs $10.8M to Expand On-Demand Nurse Staffing Management Platform
PatientPing Tool Tags BPCI Advanced Patients in Real-Time to Improve Outcomes »

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Recent Articles

  • drchrono EHR

    DrChrono Unveils EHR Configuration for Allergy Practices

    D... more
  • Propeller Health: 84% of People with Asthma May Be Using Their Inhaler Incorrectly

    Propeller Health: 84% of People with Asthma May Be Using Their Inhaler Incorrectly

    T... more
  • ICON Acquires Precision Medicine for Oncology Company MolecularMD

    ICON Acquires Precision Medicine for Oncology Company MolecularMD

    I... more

Most Read

  • Healthcare Breach Report 2016 6 Ways Health Informatics Is Transforming Health Care
  • Business Models In Healthcare 12 Defining Healthcare Trends to Watch in 2018
  • Proteus Digital Health Stanford, Proteus Releases 10 Guiding Principles for Ethics in Digital Health
  • Philips, Dispatch Health Launch On-Demand Home Care Pilot Program for Arizona Seniors Philips, DispatchHealth Launch On-Demand Home Care Pilot Program for Arizona Seniors
  • Top 10 Challenges, Issues and Opportunities for Healthcare Executives in 2019 Top 10 Challenges, Issues and Opportunities for Healthcare Executives in 2019
  • Geographic Information Systems in Healthcare 5 Benefits of Geographic Information Systems in Healthcare
  • Biomedical Engineering Trends to Watch 5 Emerging Biomedical Engineering Trends to Watch
  • New Apple Watch App Uses Algorithm to Detect Seizures & Alert Providers New Apple Watch App Uses Algorithm to Detect Seizures & Alert Providers
  • Applying Automation to Healthcare_Is the Phrase Patient Engagement Overused 6 Big Benefits of Applying Automation to Healthcare
  • Value-Based Payment Models 6 Most Common Value-Based Payment Models

Company

  • About Us
  • Advertise with Us
  • 2019 Editorial Calendar
  • Media Kit
  • Contributor Network
  • Contact
  • Subscribe

Editorial Coverage

  • Health IT
  • Policy
  • mHealth
  • Digital Health
  • Startups
  • Infographics

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2019. HIT Consultant Media. All Rights Reserved. Privacy Policy |